RETRACTED: The Association of HMGB1 Gene with the Prognosis of HCC (Retracted Article)

被引:0
作者
Xiao, Jianbiao [1 ]
Ding, Yi [1 ]
Huang, Jing [1 ,3 ]
Li, Qisheng [1 ]
Liu, Ying [1 ]
Ni, Wen [1 ]
Zhang, Yuqin [1 ]
Zhu, Yanfei [1 ]
Chen, Longhua [1 ]
Chen, Bin [2 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China
[2] Peoples Liberat Army, Guangzhou Mil Command, Gen Hosp, Dept Sci & Training, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Med Coll, Affiliated Hosp, Dept Canc Ctr, Zhanjiang, Guangdong, Peoples R China
来源
PLOS ONE | 2014年 / 9卷 / 02期
基金
中国国家自然科学基金;
关键词
MOBILITY GROUP BOX-1; RECURRENT HEPATOCELLULAR-CARCINOMA; HIGH-MOBILITY-GROUP-BOX-1; HMGB1; INCREASED EXPRESSION; CHROMATIN PROTEIN; POOR-PROGNOSIS; GASTRIC-CANCER; UNITED-STATES; CYTOKINE; CELLS;
D O I
10.1371/journal.pone.0089097
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
High-mobility group box 1 protein (HMGB1) is an evolutionarily ancient and critical regulator of cell death and survival. HMGB1 is a chromatin-associated nuclear protein molecule that triggers extracellular damage. The expression of HMGB1 has been reported in many types of cancers, but the role of HMGB1 in hepato cellular carcinoma (HCC) is unknown. The aim of this study was to analyze the roles of HMGB1 in HCC progression using HCC clinical samples. We also investigated the clinical outcomes of HCC samples with a special focus on HMBG1 expression. In an immunohistochemical study conducted on 208 cases of HCC, HMGB1 had high expression in 134 cases(64.4%). The HMGB1 expression level did not correlate with any clinicopathological parameters, except alpha fetoprotein (AFP) (p = 0.041) and CLIP stage (p = 0.007). However, survival analysis showed that the group with HMBG1 overexpression had a significantly shorter overall survival time than the group with a down-regulatedexpression of HMBG1 (HR = 0.568, CI (0.398, 0.811), p = 0.002). Multivariate analysis showed that HMGB1 expression was a significant and independent prognostic parameter (HR = 0.562, CI (0.388, 0.815), p = 0.002) for HCC patients. The ability of proliferation, migration and invasion of HCC cells was suppressed with the disruption of endogenous HMGB1 using small interfering RNAs. On the other hand, the ability of proliferation, migration and invasion of HCC cells was strengthened when the expression endogenous HMGB1 was enhanced using HMGB1 DNA. HMGB1 expression may be a novel and independent predictor for the prognosis of HCC patients. The overexpression of HMGB1 in HCC could be a novel, effective, and supplementary biomarker for HCC, since it plays a vital role in the progression of HCC.
引用
收藏
页数:10
相关论文
共 34 条
  • [1] Akaike H, 2007, ANTICANCER RES, V27, P449
  • [2] Significant (re)location: how to use chromatin and/or abundant proteins as messages of life and death
    Bianchi, ME
    [J]. TRENDS IN CELL BIOLOGY, 2004, 14 (06) : 287 - 293
  • [3] Molecular viral oncology of hepatocellular carcinoma
    Block, TM
    Mehta, AS
    Fimmel, CJ
    Jordan, R
    [J]. ONCOGENE, 2003, 22 (33) : 5093 - 5107
  • [4] HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma
    Brezniceanu, ML
    Völp, K
    Bösse, S
    Solbach, C
    Lichter, P
    Joos, S
    Zörnig, M
    [J]. FASEB JOURNAL, 2003, 17 (08) : 1295 - +
  • [5] Hepatocellular carcinoma: Trends of incidence and survival in Europe and the United States at the end of the 20th century
    Capocaccia, Riccardo
    Sant, Milena
    Berrino, Franco
    Simonetti, Arianna
    Santi, Valentina
    Trevisani, Franco
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (08) : 1661 - 1670
  • [6] Choi YR, 2003, CANCER RES, V63, P2188
  • [7] High mobility group box I (HMGB1) release from tumor cells after treatment: Implications for development of targeted chemoimmunotherapy
    Dong, Xiang Da
    Ito, Norimasa
    Lotze, Michael T.
    DeMarco, Richard A.
    Popovic, Petar
    Shand, Stuart H.
    Watkins, Simon
    Winikoff, Stephen
    Brown, Charles K.
    Bartlett, David L.
    Zeh, Herbert J., III
    [J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (06) : 596 - 606
  • [8] Hepatocellular carcinoma: Recent trends in the United States
    El-Serag, HB
    [J]. GASTROENTEROLOGY, 2004, 127 (05) : S27 - S34
  • [9] Masquerader: High mobility group box-1 and cancer
    Ellerman, Jessica E.
    Brown, Charles K.
    de Vera, Michael
    Zeh, Herbert J.
    Billiar, Timothy
    Rubartelli, Anna
    Lotze, Michael T.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (10) : 2836 - 2848
  • [10] PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection
    Kim, Do Young
    Paik, Yong Han
    Ahn, Sang Hoon
    Youn, Young Jun
    Choi, Jong Won
    Kim, Ja Kyung
    Lee, Kwan Sik
    Chon, Chae Yoon
    Han, Kwang Hyub
    [J]. ONCOLOGY, 2007, 72 : 52 - 57